Phase 4
Completed N=566
Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis
Source: ClinicalTrials.gov NCT00247962 ↗Enrolled (actual)
566
Serious AEs
—
Results posted
Nov 2012
Primary outcomePrimary: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20) — 287; 99 participants — p=<0.001
Summary
The purpose of this study is to compare the efficacy of etanercept and sulphasalazine in the treatment of Ankylosing Spondylitis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20) |
287; 99 | <0.001 sig |
| SECONDARY Ankylosing Spondylitis Quality of Life (ASQoL) Total Score Change From Baseline |
11.03; 11.32; 6.21; 9.06 | 0.719 |
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis of ankylosing spondylitis
- Active ankylosing spondylitis
Exclusion Criteria
- Complete ankylosis of spine
- Previous treatment with etanercept
Data sourced from ClinicalTrials.gov (NCT00247962). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.